keyword
MENU ▼
Read by QxMD icon Read
search

Dyslipidemia drugs

keyword
https://read.qxmd.com/read/30785916/access-to-and-price-trends-of-antidiabetic-antihypertensive-and-antilipidemic-drugs-in-outpatient-settings-of-the-universal-coverage-scheme-in-thailand
#1
Chulaporn Limwattananon, Onanong Waleekhachonloet
Under the Universal Coverage Scheme (UCS) with payment per capita for outpatient (OP) services, hospitals' financial risks will rise if access to essential drugs increases. This study examined trends in access to and price of essential drugs for noncommunicable diseases (NCDs) and an overall purchasing price index (PPI) for an OP drug basket from public hospitals. To examine drug access, OP prescription data from 2010-2012 were obtained from the UCS. Access to thirteen drugs for diabetes, hypertension, and dyslipidemia was examined for trend using a time-series analysis...
2019: PloS One
https://read.qxmd.com/read/30770220/lipid-control-and-associated-risk-factors-before-suffering-from-the-first-cardiovascular-event
#2
Pilar Ángeles Oriol Torón, Teresa Badía Farré, Amparo Romaguera Lliso
OBJECTIVE: To ascertain the degree of lipidic control before the first cardiovascular accident in population attended during 2013 at Primary Care. To analyze the distribution of these events depending on control intervals of cholesterol LDL (LDL-chol), cholesterol HDL (HDL-chol) and triglycerides (TG). METHOD: A multicentric cross-sectional, descriptive study on above 18-year-old people attended at the centres of the Primari Care Service (PCS) Baix Llobregat Nord, who had suffered a first cardiac or cerebral ischemic attack from 01/01/2013 to 31/12/2013...
February 12, 2019: Clínica e Investigación en Arteriosclerosis
https://read.qxmd.com/read/30733469/application-of-latent-class-analysis-to-identify-metabolic-syndrome-components-patterns-in-adults-tehran-lipid-and-glucose-study
#3
Noushin Sadat Ahanchi, Farzad Hadaegh, Abbas Alipour, Arash Ghanbarian, Fereidoun Azizi, Davood Khalili
In this study, using latent class analysis (LCA), we investigated whether there are any homogeneous subclasses of individuals exhibiting different profiles of metabolic syndrome (MetS) components. The current study was conducted within the framework of the Tehran Lipid and Glucose Study (TLGS), a population-based cohort including 6448 subjects, aged 20-50 years. We carried out a LCA on MetS components and assessed the association of some demographic and behavioral variables with membership of latent subclasses using multinomial logistic regression...
February 7, 2019: Scientific Reports
https://read.qxmd.com/read/30732711/modifiable-risk-factors-in-young-adults-with-first-myocardial-infarction
#4
Srikanth Yandrapalli, Christopher Nabors, Abhishek Goyal, Wilbert S Aronow, William H Frishman
BACKGROUND: Modifiable risk factors (RFs) play an important role in the development and prognosis of acute myocardial infarction (AMI). OBJECTIVES: This study sought to study the prevalence rates of modifiable RFs during a first AMI, sex/race differences, and temporal trends in U.S. young adults. METHODS: This was a retrospective cohort analysis of the U.S. National Inpatient Sample years 2005 and 2015 to identify adults 18 to 59 years of age hospitalized for a first AMI...
February 12, 2019: Journal of the American College of Cardiology
https://read.qxmd.com/read/30714088/drug-treatment-of-hyperlipidemia-in-chinese-patients-focus-on-the-use-of-simvastatin-and-ezetimibe-alone-and-in-combination
#5
REVIEW
Sheng-Na Han, Wei-Hong Yang, Jian-Jian Yin, Hai-Long Tao, Li-Rong Zhang
Elevated serum low-density lipoprotein cholesterol (LDL-C) is a major risk factor for coronary heart disease (CHD). Many guidelines recommend LDL-C as a primary treatment target, and statins represent the cornerstone of treatment for lipid management. Recently revised guidelines recommend even more intense management of LDL-C, especially in patients at moderate and high risk. However, LDL-C levels in the Chinese population differ from those in Western populations, and the benefits and safety of the maximum allowable dose of statins have yet to be determined...
February 4, 2019: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/30706799/current-therapy-and-nutraceuticals-for-the-treatment-of-patients-with-dyslipidemias
#6
Michele Scognamiglio, Dario Costa, Antonio Sorriento, Claudio Napoli
Coronary heart disease (CHD) remain the leading cause of disability and death in industrialized Countries. Among many conditions that contribute to the etiology and progression of CHD, the presence of high LDL-C levels represent the major risk factor. Therefore, the reduction of LDL-C levels play a key role in the management of patients with high or very high cardiovascular risk. Although statins represent the gold standard therapy for the reduction of cholesterol levels, do not allow to achieve target levels of LDL-C in all patients...
January 29, 2019: Current Pharmaceutical Design
https://read.qxmd.com/read/30704254/combined-lipid-lowering-therapy
#7
David Karásek
Dyslipidemia belongs to the main risk factors for atherosclerosis. To achieve current blood lipid targets, it is often necessary to use intensive hypolipidemic therapy including a combination of individual hypolipidemic drugs. In terms of cardiovascular risk reduction, it is important that the patient is treated with the highest tolerated dose of statin. In the next step, we decide to co-administer ezetimibe and/or fibrate, and for high-risk patients an additional treatment with proprotein convertase subtilisin kexin 9 inhibitors should be considered...
2019: Vnitr̆ní Lékar̆ství
https://read.qxmd.com/read/30704253/why-not-to-interfere-with-ldl-cholesterol-freefall-and-why-not-to-talk-badly-about-statins
#8
Jan Piťha
Thanks to new drugs and treatments it is now possible, and therefore also advisable, to achieve very low LDL-cholesterol levels. This is primarily the inhibition of the proproteinconvertase subtilisin kexin 9 and LDL apheresis. Despite these new procedures, they remain the main antagonist of atherosclerosis and atherogenic dyslipidemia of statins. Statins are the basis of treatment always. If they are not enough or if they actually cause uncontrollable difficulties, they can be supplemented or replaced by other medications or treatments that reduce values of LDL-cholesterol...
2019: Vnitr̆ní Lékar̆ství
https://read.qxmd.com/read/30704246/consensus-statement-of-professional-associations-on-prescribing-of-pcsk9-inhibitors
#9
Richard Češka, Miloš Táborský, Michal Vrablík
A new class of drugs known as PCSK9 inhibitors (PCSK9i) provide biological treatment for hypercholesterolemia. These drugs are administered using a subcutaneous injection once in two or four weeks. PCSK9i are not a replacement of the existing hypolipidemics, they just expand the therapeutic spectrum for the critically ill and those who cannot use the standard therapy and do not reach satisfactory target values. There are essentially two indications: (1) hypercholesterolemie and mixed dyslipidemia and (2) secondary prevention of cardiovascular diseases (CVD)...
2019: Vnitr̆ní Lékar̆ství
https://read.qxmd.com/read/30702996/lipid-lowering-agents
#10
Robert A Hegele, Sotirios Tsimikas
Several new or emerging drugs for dyslipidemia owe their existence, in part, to human genetic evidence, such as observations in families with rare genetic disorders or in Mendelian randomization studies. Much effort has been directed to agents that reduce LDL (low-density lipoprotein) cholesterol, triglyceride, and Lp[a] (lipoprotein[a]), with some sustained programs on agents to raise HDL (high-density lipoprotein) cholesterol. Lomitapide, mipomersen, AAV8.TBG.hLDLR, inclisiran, bempedoic acid, and gemcabene primarily target LDL cholesterol...
February 2019: Circulation Research
https://read.qxmd.com/read/30696435/blood-pressure-and-low-density-lipoprotein-cholesterol-control-status-in-chinese-hypertensive-dyslipidemia-patients-during-lipid-lowering-therapy
#11
Xiaowei Yan, Yong Li, Yugang Dong, Yanhua Wu, Jihu Li, Rui Bian, Dayi Hu
ᅟ: The present study comprised 17,096 Chinese hypertensive dyslipidemia patients who received lipid-lowering treatment for > 3 months in order to investigate blood pressure (BP) as well as low-density lipoprotein cholesterol (LDL-C) goal attainment rates in Chinese hypertensive dyslipidemia patients on antidyslipidemia drugs. The factors that interfered with BP, or BP and LDL-C goal attainment rates and antihypertensive treatment patterns, were analyzed. In total, 89.9% of the 17,096 hypertensive dyslipidemia patients received antihypertensive medications mainly consisting of a calcium channel blocker (CCB) (48...
January 29, 2019: Lipids in Health and Disease
https://read.qxmd.com/read/30694825/dyslipidemia-in-nonalcoholic-fatty-liver-disease
#12
Antonio J Amor, Verónica Perea
PURPOSE OF REVIEW: To summarize recent findings regarding the characterization of lipoprotein disturbances in nonalcoholic fatty liver disease (NAFLD) and their relationship with cardiovascular disease (CVD) and make recommendations for the management of this situation. RECENT FINDINGS: Advanced lipoprotein profile (using NMR spectroscopy) has shown profound lipoprotein derangements which are overlooked with conventional analyses: increased number and size of very low-density lipoproteins particles, increased number of low-density lipoprotein particles (especially small sized), smaller high-density lipoprotein particles, and an increase in the triglyceride content of all these lipoproteins...
January 28, 2019: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/30685356/hepatic-carboxylesterases-are-differentially-regulated-in-ppar%C3%AE-null-mice-treated-with-perfluorooctanoic-acid
#13
Xia Wen, Angela A Baker, Curtis D Klaassen, J Christopher Corton, Jason R Richardson, Lauren M Aleksunes
Hepatic carboxylesterases (Ces) catalyze the metabolism of drugs, environmental toxicants, and endogenous lipids and are known to be regulated by multiple nuclear receptors. Perfluorooctanoic acid (PFOA) is a synthetic fluorochemical that has been associated with dyslipidemia in exposed populations. In liver, PFOA can activate nuclear receptors such as PPARα, and alter the metabolism and excretion of chemicals. Here, we sought to test the ability of PFOA to modulate Ces expression and activity in the presence and absence of the PPARα receptor...
January 24, 2019: Toxicology
https://read.qxmd.com/read/30677459/non-nucleoside-reverse-transcriptase-inhibitor-efavirenz-activates-pxr-to-induce-hypercholesterolemia-and-hepatic-steatosis
#14
Taesik Gwag, Zhaojie Meng, Yipeng Sui, Robert N Helsley, Se-Hyung Park, Shuxia Wang, Richard N Greenberg, Changcheng Zhou
BACKGROUND & AIMS: The most prescribed non-nucleoside reverse transcriptase inhibitor efavirenz has been associated with elevated risk for dyslipidemia and hepatic steatosis in HIV-infected patients but the underlying mechanisms remain elusive. Here we investigated the role of pregnane X receptor (PXR) in mediating the adverse effects of efavirenz on lipid homeostasis. METHODS: Cell-based reporter assays, primary cell culture, and multiple mouse models including conditional knockout and humanized mice were combined to study the impact of efavirenz on PXR activities and lipid homeostasis in vitro and in vivo...
January 21, 2019: Journal of Hepatology
https://read.qxmd.com/read/30677262/clinical-considerations-regarding-the-use-of-obesity-pharmacotherapy-in-adolescents-with-obesity
#15
REVIEW
Gitanjali Srivastava, Claudia K Fox, Aaron S Kelly, Ania M Jastreboff, Allen F Browne, Nancy T Browne, Janey S A Pratt, Christopher Bolling, Marc P Michalsky, Stephen Cook, Carine M Lenders, Caroline M Apovian
A growing number of youth suffer from obesity and in particular severe obesity for which intensive lifestyle intervention does not adequately reduce excess adiposity. A treatment gap exists wherein effective treatment options for an adolescent with severe obesity include intensive lifestyle modification or metabolic and bariatric surgery while the application of obesity pharmacotherapy remains largely underutilized. These youth often present with numerous obesity-related comorbid diseases, including hypertension, dyslipidemia, prediabetes/type 2 diabetes, obstructive sleep apnea, nonalcoholic fatty liver disease, musculoskeletal problems, and psychosocial issues such as depression, anxiety, and social stigmatization...
February 2019: Obesity
https://read.qxmd.com/read/30674032/pharmacology-of-dipeptidyl-peptidase-4-inhibitors-and-its-use-in-the-management-of-metabolic-syndrome-a-comprehensive-review-on-drug-repositioning
#16
Maryam Rameshrad, Bibi Marjan Razavi, Gordon A A Ferns, Hossein Hosseinzadeh
OBJECTIVES: Despite advances in our understanding of metabolic syndrome (MetS) and the treatment of each of its components separately, currently there is no single therapy approved to manage it as a single condition. Since multi-drug treatment increases drug interactions, decreases patient compliance and increases health costs, it is important to introduce single therapies that improve all of the MetS components. EVIDENCE ACQUISITION: We conducted a PubMed, Scopus, Google Scholar, Web of Science, US FDA, utdo...
January 23, 2019: Daru: Journal of Faculty of Pharmacy, Tehran University of Medical Sciences
https://read.qxmd.com/read/30670286/soy-milk-a-functional-beverage-with-hypocholesterolemic-effects-a-systematic-review-of-randomized-controlled-trials
#17
REVIEW
Omid Eslami, Farzad Shidfar
OBJECTIVE: Current guidelines have highlighted the role of diet in conjunction with drug therapy in the management of dyslipidemia. Over the last two decades, the effect of soy milk, a derivative of soybean, on blood lipids has been the focus of nutritional researches. The present study aimed to provide a comprehensive review of clinical trials investigating the effect of soy milk on blood lipids. METHODS: An electronic database searching including PubMed, EMBASE, Scopus, and CENTRAL was performed to extract all the records that were published up to May 2018 using MeSH terms and relevant keywords...
February 2019: Complementary Therapies in Medicine
https://read.qxmd.com/read/30668411/medicinal-plants-in-treatment-of-hypertriglyceridemia-a-review-based-on-their-mechanisms-and-effectiveness
#18
REVIEW
Hamid Mollazadeh, Davood Mahdian, Hossein Hosseinzadeh
BACKGROUND: Hypertriglyceridemia (HTg) defines as high amounts of triglyceride (TG) in the blood which can lead to serious complications over time. HTg is usually a part of metabolic disorders such as diabetes mellitus, metabolic syndrome, and dyslipidemia. Different medications have been used to treat HTg but experimentally, many herbs have been recommended for treating HTg as an adjuvant therapy. In most cases, the recommendations are based on animal studies and limited evidences exist about their mechanisms and clinical usefulness...
September 5, 2018: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
https://read.qxmd.com/read/30668392/yangonin-protects-against-non-alcoholic-fatty-liver-disease-through-farnesoid-x-receptor
#19
Renchao Dong, Xiaobo Yang, Changyuan Wang, Kexin Liu, Zhihao Liu, Xiaodong Ma, Huijun Sun, Xiaokui Huo, Ting Fu, Qiang Meng
BACKGROUD: Non-alcoholic fatty liver disease (NAFLD) is currently evolving as the most common liver disease worldwide. Dyslipidemia, pathoglycemia and insulin resistance are the major risk factors for the development of NAFLD. To date, no effective drug therapies for this condition have been approved. PURPOSE: The present study was to investigate the protective effects of yangonin, a kavalactone isolated from Kava, against NAFLD and further elucidate the mechanisms in vivo and in vitro...
September 5, 2018: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
https://read.qxmd.com/read/30665829/efficacy-and-safety-of-triple-therapy-with-telmisartan-amlodipine-and-rosuvastatin-in-patients-with-dyslipidemia-and-hypertension-the-jeil-telmisartan-amlodipine-and-rosuvastatin-randomized-clinical-trial
#20
Soon Jun Hong, Han Saem Jeong, Jin-Man Cho, Kiyuk Chang, Wook Bum Pyun, Youngkeun Ahn, Min Su Hyon, Woong Chol Kang, Jae-Hwan Lee, Hyo-Soo Kim
PURPOSE: Fixed-dose combination therapy with telmisartan, amlodipine, and rosuvastatin is needed in patients with hypertension and dyslipidemia for better adherence and cost-effectiveness than free-equivalent combination therapies. This study aimed to compare the efficacy and safety of combination therapy with telmisartan, amlodipine, and rosuvastatin versus telmisartan plus amlodipine or telmisartan plus rosuvastatin in patients with hypertension and dyslipidemia. METHODS: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial (J-TAROS-RCT) was an 8-week, multicenter, randomized, double-blind, parallel, Phase III clinical trial conducted at 9 hospitals in Korea...
January 18, 2019: Clinical Therapeutics
keyword
keyword
168067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"